Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences.
Kivistö
K T
KT
Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
Neuvonen
P J
PJ
Klotz
U
U
D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D015725:Fluconazole / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects; D006801:Humans; D017964:Itraconazole / Q000494:pharmacology*; D007654:Ketoconazole / Q000494:pharmacology*; D011355:Prodrugs / Q000009:adverse effects / Q000493:pharmacokinetics*; D016593:Terfenadine / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics*
D011355:Prodrugs; D017964:Itraconazole; D016593:Terfenadine; D015725:Fluconazole; D003577:Cytochrome P-450 Enzyme System; D007654:Ketoconazole